JWJun Wan

Jun Wan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Wan has a total of 134 co-authors. Here are the top co-authors by number of shared publications:

  • Yao Xu

    Department of Cardiology Renmin Hospital of Wuhan University Wuhan China

    55 shared publications
  • Jianfang Liu

    Department of Cardiology Renmin Hospital of Wuhan University Wuhan China

    54 shared publications
  • Jishou Zhang

    Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute, Wuhan University, Wuhan, China; Hubei Key Laboratory of Cardiology, Wuhan, China

    47 shared publications
  • Menglong Wang

    Department of Cardiology, Renmin Hospital of Wuhan University , 238 Jiefang Road, Wuhan 430060

    46 shared publications
  • Mengmeng Zhao

    Department of Cardiology Renmin Hospital of Wuhan University Wuhan China

    44 shared publications
  • Di Ye

    Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan, 430060, China

    43 shared publications

Latest Publications

  • Maresin 2 Attenuates Hypertensive Vascular Remodeling via Inhibiting Macrophage Infiltration and Pro‐fibrotic Polarization

    by Shanshan Peng, Tao Wang, Jianfang Liu, Mengmeng Zhao, Zican Shen, Siqi Liu, Cheng Wei, Zihui Zheng, Yao Xu, Jun Wan, et al.

    Immune‐inflammatory responses are pivotal regulators of hypertensive vascular remodeling. Specialized pro‐resolving mediators (SPMs), including Maresin 2 (MaR2), are endogenous anti‐inflammatory molecules. However, the specific role of MaR2 in regulating hypertension and vascular remodeling, as well as its underlying mechanisms, remains unclear. In this study, a murine model of hypertension was induced by continuous infusion of Angiotensin II (AngII) at 1 μg/kg/min. MaR2 intervention (2 μg/kg/day) was administered either prophylactically (before model induction) or therapeutically (after model induction). Prophylactic MaR2 effectively prevented AngII‐induced blood pressure elevation and vascular remodeling. Similarly, therapeutic administration after the establishment of hypertension with MaR2 significantly lowered blood pressure and attenuated medial thickening and fibrosis in the aorta and mesenteric arteries. Mechanistic studies revealed that MaR2 significantly inhibited macrophage infiltration and inflammatory responses within vascular tissues. Further in vitro and in vivo experiments confirmed that MaR2 effectively suppressed AngII‐induced macrophage polarization toward a pro‐fibrotic phenotype and reduced the acquisition of a myofibroblast‐like phenotype (i.e., α‐SMA expression) by macrophages by blocking the TGF‐β/Smad3 signaling pathway. Notably, pharmacological activation of TGF‐β/Smad signaling using SRI011381 partially counteracted the protective effects of MaR2 on vascular remodeling. MaR2 attenuates AngII‐induced hypertension and vascular remodeling in association with reduced vascular macrophage accumulation and suppression of macrophage pro‐fibrotic polarization, at least partly through regulation of TGF‐β/Smad3 signaling. These findings identify MaR2 as a candidate pro‐resolving intervention in an AngII‐induced murine model of hypertension and support further mechanistic and translational evaluation in hypertension‐associated vascular remodeling.


  • IL-22 mediated immuno-vascular crosstalk aggravates Ang II induced hypertension in mice via ferritinophagy

    by Yongqi Feng, Liren Gan, Yibo Wang, Heng Pan, Xiyi Lu, Di Ye, Jun Wan, Jing Ye


  • Kielin/chordin-like protein(KCP) deficiency exacerbates doxorubicin-induced myocardial injury by promoting macrophage M1 polarization through autophagy inhibition

    by Yibo Wang, Qingwei Ji, Liren Gan, Yongqi Feng, Heng Pan, Xiyi Lu, Jing Ye, Lingyue Qiu, Qingkuan Li, Jianwei Zhang, et al.

  • Open Access

    Leucine‐Rich Repeat‐Containing G Protein‐Coupled Receptor 6 Ameliorates Pressure Overload‐Induced Cardiac Hypertrophy by Regulating Cardiomyocyte Metabolic Reprogramming

    by Mengmeng Zhao, Jianfang Liu, Shanshan Peng, Zihui Zheng, Siqi Liu, Jun Wan, Yao Xu, Menglong Wang

    Metabolic reprogramming is a pivotal mechanism in the pathogenesis of pathological cardiac hypertrophy. Leucine‐rich repeat‐containing G protein‐coupled receptor 6 (Lgr6) has emerged as a significant player in cardiovascular diseases. In this study, the potential of Lgr6 to counteract pressure overload (PO)‐induced cardiac hypertrophy is investigated, and the underlying mechanisms involved are elucidated. Transverse aortic constriction (TAC) is induced to establish an in vivo cardiac hypertrophy model. Adeno‐associated virus 9 and adenovirus vectors are utilized to knock down and overexpress Lgr6 in cardiomyocytes, respectively. The effects of Lgr6 and its downstream molecules are subsequently determined using RNA sequencing and chromatin immunoprecipitation. Significant downregulation of Lgr6 expression is observed in the heart after TAC and in cardiomyocytes treated with phenylephrine. Lgr6 deficiency accelerated and Lgr6 overexpression inhibits cardiac hypertrophy and dysfunction after TAC. Mechanistically, the in vivo and in vitro experiments suggest that Lgr6 regulates the expression of ubiquitin specific protease 4 (USP4) and peroxisome proliferator‐activated receptor alpha (PPARα) by activating the cGMP/PKG/CREB1 signalling pathway, thereby regulating cardiomyocyte metabolic reprogramming after PO. Targeting Lgr6 can be a potential therapeutic strategy to treat pathological cardiac hypertrophy.


  • Semi-Supervised CT Denoising via Text-Guided Mamba Diffusion Models

    by Bo Su, Xiangyun Hu, Jiabo Xu, Kai Deng, Yunfei Zha, Jun Wan

    Low-dose computed tomography reduces patient radiation exposure, yet it introduces noise and artifacts that can impair diagnostics. Recent supervised methods, particularly the diffusion method, have effectively minimized image smoothing while preserving details. However, iterative sampling incurs considerable time costs. In addition, obtaining a large number of paired low-dose and normal-dose CT images is clinically challenging, and imaging results vary across different body regions and devices.We propose a novel semi-supervised diffusion model. In addition, we design textual information related to different anatomical regions and devices in the denoising task and develop a text-guided approach that enables the model to generate accurate denoising results without requiring separate models for each region or device. An asymmetric encoder-decoder architecture has been implemented, featuring an encoder based on the State Space Model to enhance noise prediction capabilities. Furthermore, to increase sampling efficiency, a redraw feature has been proposed during the sampling process. It enables adjustment of the redraw rate according to the noise levels, ensuring detailed image preservation while significantly reducing time. We scanned head and chest phantoms using two devices, GE and Siemens, under two low-dose settings (10% and 25%), acquiring a total of 13,499 slices. The phantom dataset used for evaluation was scanned independently of the training set, including a total of 1400 images from two sites of two devices. Our approach is superior to the partially unsupervised and supervised methods by processing various body parts and device slices and is 100 times faster than Denoising Diffusion Probabilistic Models (DDPM).


  • Open Access

    Resolvin D2/GPR 18 axis ameliorates pressure overload-induced heart failure by inhibiting pro-inflammatory macrophage polarization

    by Zihui Zheng, Mengmeng Zhao, Yao Xu, Jishou Zhang, Shanshan Peng, Jianfang Liu, Wei Pan, Zheng Yin, Cheng Wei, Juan-Juan Qin, et al.


  • Open Access

    LGR6 protects against myocardial ischemia-reperfusion injury via suppressing necroptosis

    by Mengmeng Zhao, Zihui Zheng, Jianfang Liu, Yao Xu, Jishou Zhang, Shanshan Peng, Juan-Juan Qin, Jun Wan, Menglong Wang


  • Interleukin-12p40 deficiency attenuates myocardial ferroptosis in doxorubicin-induced chronic cardiomyopathy by inhibiting Th17 differentiation and interleukin-17A production

    by Jishou Zhang, Wen Ding, Zheng Yin, Siqi Liu, Mengmeng Zhao, Yao Xu, Jianfang Liu, Wei Pan, Shanshan Peng, Cheng Wei, et al.

    Aims: Interleukin (IL)-12p40 is a common subunit of the bioactive cytokines IL-12 and IL-23, and it also has its own intrinsic functional activity. However, its role in doxorubicin-induced chronic cardiomyopathy (DICCM) as well as the underlying mechanisms are still unknown. Methods and results: In this study, we used IL-12p40-knockout mice, IL-23p19-knockout mice, Rag1-knockout mice, a ferroptosis inhibitor, recombinant IL-12 (rIL-12), rIL-23, rIL-12p40, rIL-12p80, and anti-IL17A to investigate the effects of IL-12p40 on DICCM and elucidate the underlying mechanisms. We found that myocardial ferroptosis were increased in DICCM and that the inhibition of ferroptosis protected against DICCM. The expression of IL-12p40 was upregulated, and IL-12p40 was predominantly expressed by CD4+ T cells in the hearts of mice with DICCM. IL-12p40 knockout attenuated cardiac dysfunction, fibrosis and ferroptosis in DICCM, and similar results were observed in the context of CD4+ T cell IL-12p40 deficiency in Rag1−/− mice. Treatment with rIL-23, but not rIL-12, rIL-12p40 monomer or rIL-12p80, abolished the protective effects of IL-12p40 knockout. Moreover, rIL-23 treatment and IL-23p19 knockout exacerbated and ameliorated DICCM, respectively. IL-12p40 knockout might protect against DICCM by inhibiting Th17 differentiation and IL-17A production but not Th1, Th2 and Treg differentiation. Neutralizing IL-17A with an antibody also attenuated cardiac dysfunction, fibrosis, and ferroptosis. The IL-12p40/Th17/IL-17A axis might promote cardiomyocyte ferroptosis by activating TNF receptor-associated factor 6 (TRAF6)/mitogen-activated protein kinase (MAPK)/P53 signalling in DICCM. Conclusion: Interleukin-12p40 deficiency protects against DICCM by inhibiting Th17 differentiation and the production of IL-17A, which plays critical roles in cardiomyocyte ferroptosis in DICCM via activating TRAF6/MAPK/P53 signalling. Our study may provide novel insights for the identification of therapeutic targets for treating DICCM in the clinic.


  • Cardiomyocyte LGR6 alleviates ferroptosis in diabetic cardiomyopathy via regulating mitochondrial biogenesis

    by Mengmeng Zhao, Zican Shen, Zihui Zheng, Yao Xu, Jishou Zhang, Jianfang Liu, Shanshan Peng, Jun Wan, Juan-Juan Qin, Menglong Wang


  • Open Access

    Regulated vascular smooth muscle cell death in vascular diseases

    by Zheng Yin, Jishou Zhang, Zican Shen, Juan‐Juan Qin, Jun Wan, Menglong Wang

    Regulated cell death (RCD) is a complex process that involves several cell types and plays a crucial role in vascular diseases. Vascular smooth muscle cells (VSMCs) are the predominant elements of the medial layer of blood vessels, and their regulated death contributes to the pathogenesis of vascular diseases. The types of regulated VSMC death include apoptosis, necroptosis, pyroptosis, ferroptosis, parthanatos, and autophagy‐dependent cell death (ADCD). In this review, we summarize the current evidence of regulated VSMC death pathways in major vascular diseases, such as atherosclerosis, vascular calcification, aortic aneurysm and dissection, hypertension, pulmonary arterial hypertension, neointimal hyperplasia, and inherited vascular diseases. All forms of RCD constitute a single, coordinated cell death system in which one pathway can compensate for another during disease progression. Pharmacologically targeting RCD pathways has potential for slowing and reversing disease progression, but challenges remain. A better understanding of the role of regulated VSMC death in vascular diseases and the underlying mechanisms may lead to novel pharmacological developments and help clinicians address the residual cardiovascular risk in patients with cardiovascular diseases.